ProQR Therapeutics (PRQR) Long-Term Debt Issuances (2013 - 2021)

ProQR Therapeutics has disclosed Long-Term Debt Issuances across 9 years of filings, most recently posting $30.3 million for Q4 2021.

• Long-Term Debt Issuances for Q4 2021 came in at $30.3 million, up 10111.27% year-over-year; the trailing twelve-month figure through Dec 2021 was $31.6 million (up 93.38% YoY), and the FY2021 annual result was $1.3 million, up 103.53% from the prior year.
• Long-Term Debt Issuances came in at $30.3 million for Q4 2021 at ProQR Therapeutics, up from $334917.6 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $30.3 million in Q4 2021 to a low of $117.51 in Q3 2017.
• The 5-year median for Long-Term Debt Issuances is $217063.1 (2018), against an average of $3.1 million.
• Across the five-year window, Long-Term Debt Issuances plunged 99.97% in 2017 and surged 795346.26% in 2019, its largest moves.
• ProQR Therapeutics' Long-Term Debt Issuances stood at $117.74 in 2017, then soared by 58.01% to $186.05 in 2018, then soared by 795346.26% to $1.5 million in 2019, then tumbled by 79.94% to $296880.2 in 2020, then soared by 10111.27% to $30.3 million in 2021.
• The last three Long-Term Debt Issuances figures came in at $30.3 million (Q4 2021), $334917.6 (Q3 2021), and $685230.4 (Q2 2021), per Business Quant data.